Core Insights - The probiotic industry is increasingly relying on clinical evidence as a foundation for development, driven by consumer awareness, regulatory standardization, and the demand for genuine product value [1] - The Bifidobacterium animalis subsp. lactis BLa80 strain, isolated from healthy breast milk in China's Sichuan Plateau, has established a comprehensive scientific evidence system and has been officially listed for infant food use [2][4] - BLa80 has successfully passed both self-affirmed GRAS and FDA GRAS certifications, marking it as the first strain in mainland China to achieve dual GRAS status, which enhances the domestic probiotic industry and reduces reliance on imported strains [2][5] Industry Trends - The focus of probiotic research has shifted from broad strain categories to precise validation of specific strain functions, emphasizing the importance of a complete evidence chain from safety assessments to clinical trials and regulatory approvals [8] - The development model of BLa80, which integrates local microbial resources, international and domestic certifications, and comprehensive clinical research covering the entire infant growth cycle, is expected to drive quality improvement and technological advancement in the domestic probiotic industry [8]

7月19日，第十二届休闲食品科技创新与产业发展大会在福建晋江隆重召开，会上益 生菌科技的前沿应用成为焦点。微康益生菌研究院赵云蛟博士受邀发表主题报告 《"益生菌+"赋能休闲食品 营养健康升级的创新设计思路》，为行业带来突破性解决 方案。 面对消费者对健康零食高达76%的需求增长，赵云蛟博士指出："'益生菌+'战略通过 产品形式多样化拓展应用边界，实现休闲食品健康化升级与功能食品日常化融合，是 构建差异化竞争壁垒的关键。" 微康益生菌研究院依托深厚研发底蕴，展示了其核心菌株矩阵的硬核科技实力： 动物双歧杆菌乳亚种BLa80：从婴幼儿到老年，科学守护人生每一程，完成婴儿健 康、改善IBS、护胃清幽、调节肠道菌群等方向的临床研究20余项，并拥有24+篇SCI 论文、13+项专利护航婴童过敏防护与免疫调节，是中国大陆首株获双GRAS（self- affirmed GRAS和FDA GRAS）认证的婴幼儿菌株。 嗜黏蛋白阿克曼氏菌Akk11：被誉为"下一代减肥瘦子菌"AKK11，以10余项专利、 5+项临床研究证实其调节食欲、改善肥胖及代谢水平的潜力，助您轻松享"瘦"健康， 可提供活菌/灭活双形态高活性原料。 基于强大 ...